

OUR MISSION

Astellas Oncology is committed to elevating the standard of cancer care. We focus on innovative therapies for hard-to-treat cancers with limited treatment options, which is where we see the greatest promise—and the greatest opportunity to change lives.

We pride ourselves on our:



Boundless Innovation



Thoughtful Collaboration



Community Commitment

OUR INVESTIGATIONAL PIPELINE

Our current investigational pipeline represents a broad range of scientific thinking. Visit stellasoncology.com/#pipeline to see the status of each discovery compound.

TUMOR TYPE	MODALITY	COMPOUND
Prostate	Androgen receptor inhibitor	Enzalutamide
Gastric, Pancreatic	Monoclonal antibody	Zolbetuximab
Acute Myeloid Leukemia (AML)	FLT3 inhibitor	Gilteritinib
Urothelial (and other solid tumor types)	Antibody-drug conjugate	Enfortumab vedotin
Multiple Tumor Types	Immuno-oncology	Early-stage programs

The safety and efficacy of these agents under investigation have not been established for the use(s) being considered. There is no guarantee that the agent will receive regulatory approval and become commercially available for the use being investigated.

C³ PRIZE

Since 2016, Astellas has provided grants, support, and resources to innovative thinkers in the cancer community to fund the best ideas in cancer care beyond medicine.



For information about this year's prize, please visit stellasoncology.com/c3prize

stellasoncology.com

MEDIA CONTACT // 800-888-7704

corporate.communications@astellas.com

AstellasUS @AstellasUS @AstellasUS

OUR CULTURE

It's an exciting time at Astellas Oncology, where our culture encourages each of us to think boldly and work differently to make every day better for those impacted by cancer. Together, we are able to accelerate the promise of changing lives.

Astellas is consistently recognized as a great place to work.

